FGP
DNTH icon

Freestone Grove Partners’s Dianthus Therapeutics DNTH Stock Holding History

Freestone Grove Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.1M Buy
+239,943
New +$13.9M 0.14% 208

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Freestone Grove Partners's DNTH Position: Q1 2026 in Review

Freestone Grove Partners opened a new position in Dianthus Therapeutics (DNTH) in Q1 2026: 239,943 shares worth $20.1M. The stake represents 0.14% of the portfolio and ranks #208 among its holdings.

241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Freestone Grove Partners held 239,943 shares of Dianthus Therapeutics worth $20.1M as of Q1 2026.
  • Dianthus Therapeutics was a new Freestone Grove Partners position in Q1 2026.
  • Dianthus Therapeutics made up 0.14% of Freestone Grove Partners's portfolio in Q1 2026, its #208 holding.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.